Abirapro 250 mg Tablet 120's is an anti-androgen medicine used in the treatment of prostate cancer. It is used to treat metastatic castration-resistant prostate cancer (a condition where cancer does not get controlled with hormonal therapy) and metastatic castration-sensitive prostate cancer (a condition where cancer has spread to other parts of the body but can be controlled) in men. Prostate cancer is a condition that occurs when the prostate gland cells increase abnormally. Symptoms may include difficulty in urinating, pain, numbness, etc.
Abirapro 250 mg Tablet 120's contains Abiraterone acetate, which belongs to the class of androgen biosynthesis inhibitors. Testosterone is a natural hormone produced by the body. This causes an increase in cancer cells in the prostate gland. Abirapro 250 mg Tablet 120's works by inhibiting the production of the testosterone hormone and thus stops the growth and spread of cancer.
Abirapro 250 mg Tablet 120's may cause certain side effects such as nausea, dizziness, heartburn, headache, diarrhoea, muscle weakness, joint pain, confusion, hot flushes, loss of appetite and groin pain. These side effects usually disappear without any medical attention. However, if these side effects persist, inform your doctor. Take this medicine as advised by your doctor. It should be taken on an empty stomach at least 2 hours before or after meals. Your doctor will decide the dose of the medicine based on the severity of your disease.
Abirapro 250 mg Tablet 120's should be avoided if you are allergic to it. Inform your doctor if you have any pre-existing or a history of liver/kidney disease, cardiovascular disease, adrenocortical insufficiency, hypokalemia, hypoglycaemia, fluid retention before taking Abirapro 250 mg Tablet 120's. Abirapro 250 mg Tablet 120's is not recommended for use in women and children as the safety and efficacy of this medicine are not established. Inform your doctor of all your ongoing medications to avoid interactions. This medicine is used in combination with prednisolone for the treatment of prostate cancer.